The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s law protecting 340B pricing for contract pharmacy arrangements. The two companies were also denied a preliminary injunction in Maine last week.

Judge John McConnell Jr. delivered the order from the bench. “The drug manufacturers have tested other similar state statutes through lawsuits and requests for injunctive relief based on the same or similar legal claims,” he said. “This court has reviewed the statutes, case law, the parties’ briefs, as well as amicus briefs. Based on its own reasoning and that of its sister courts, the court agrees that the plaintiffs are not likely to succeed on the merits of their claim.” 

The AHA filed amicus briefs (AbbVie, Novartis) in these cases opposing the drug companies’ motions and has opposed similar challenges by drug companies in multiple states.

Perspective
Public
As we move into the second half of 2026 and Congress returns to work in Washington, D.C., next week, lawmakers face a list of difficult issues that demand…
Headline
The Centers for Medicare & Medicaid Services July 2 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system…
Headline
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.In a statement…
Headline
The 4th U.S. Circuit Court of AppealsMay 28 agreed to rehear challenges to 340B contract pharmacy laws from West Virginia and Maryland. In April, a three-judge…
Headline
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 editorial criticizing the 340B Drug…
Headline
The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a functional third-party…